Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Artikel i vetenskaplig tidskrift, 2013
Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression (SP).
Objective: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first generation disease modifying drugs (DMDs), and a historical control cohort.
Methods: We included a cohort of contemporary RRMS patients treated with DMDs, obtained from the Swedish National MS Registry (disease onset between 1995–2004, n = 730) and a historical population-based incidence cohort (onset 1950–64, n = 186). We retrospectively analyzed the difference in time to SP, termed the “period effect” within a 12-year survival analysis, using Kaplan-Meier and Cox regression analysis.
Results: We found that the “period” affected the entire severity spectrum. After adjusting for onset features, which were weaker in the contemporary material, as well as the therapy initiation time, the DMD-treated patients still exhibited a longer time to SP than the controls (hazard ratios: men, 0.32; women, 0.53).
Conclusion: Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given
SPMS
RRMS
progression
multipel skleros
bromsmedicin
DMD
Författare
Helen Tedeholm
Göteborgs universitet
Jan Lycke
Göteborgs universitet
Bengt Skoog
Göteborgs universitet
Vera Lisovskaja
Göteborgs universitet
Chalmers, Matematiska vetenskaper, Matematisk statistik
J Hillert
Karolinska universitetssjukhuset
C Dahle
Linköpings universitet
J Fagius
Akademiska Sjukhuset
S Fredrikson
Karolinska universitetssjukhuset
A-M Landtblom
Linköpings universitet
Clas Malmeström
Göteborgs universitet
C Martin
Danderyds sjukhus
F Piehl
Karolinska universitetssjukhuset
Björn Runmarker
Göteborgs universitet
L Stawiarz
Karolinska universitetssjukhuset
M Vrethem
Linköpings universitet
Olle Nerman
Chalmers, Matematiska vetenskaper, Matematisk statistik
Göteborgs universitet
Oluf Andersen
Göteborgs universitet
Multiple Sclerosis
1352-4585 (ISSN) 1477-0970 (eISSN)
Vol. 19 6 765-774Ämneskategorier
Klinisk medicin
DOI
10.1177/1352458512463764
PubMed
23124789